GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 551-555

  Atzpodien, Jens ^a,b   Reitz, Martina ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Europaisches Institut fur Tumor Immunologie und Pravention EUTIP   (Germany)

Author keywords

GM CSF; Melanoma; Peptide vaccination

Indexed keywords

BERLEX; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; MELAN A; MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; BONE PAIN; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; ERYTHEMA; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MALE; MELANOMA; MELANOSOME; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN PRURITUS; VACCINATION;

ADULT; AGED; CANCER VACCINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34548616074     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.376     Document Type: Article

References (18)

1. Kirkwood JM, Strawdermann MH, Ernstoff MS, et al. Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7.
2. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cane 1999;80:219.
3. Kirkwood JM, Lee S, Land S, et al. E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multiepitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-370D) (MGT) ± IFNalfa2b and GM-CSF. [Abstract 7502] ASCO-Meeting. New Orleans, June 6, 2004:707.
4. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006;106:1353.
5. Atzpodien J, Fluck M, Reitz M. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Cancer Biother Radiopharm 2004;19:758.
6. Letsch A, Scheibenbogen C, Fluck M, et al. Adjuvant tyrosinase peptide vaccination in patients with resected stage III/IV melanoma. [Abstract 2570] ASCO-Annual Meeting, Proceedings, Part I. Atlanta, GA, June 20, 2006:24(18S).
7. Fluck M, Kamanabrou D, Lippold A, et al. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Cancer Biother Radiopharm 2005;20:280.
8. Schild H, Deres K, Wiesmuller KH, et al. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic cells. Eur J Immunol 1991;21:2649.
9. Lamm DL. Laboratory and clinical experience with key-hole limpet hemocyanin (Immucothel) in superficial bladder cancer. J Urol Urogynäkol (Ausgabe für Deutschland) 2003;10:13.
10. 280-288 peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Canc Res 2001;7:3012.
11. Weber J, Sondak VK, Scotland R, et al. Granuloyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186.
12. Stritzke J, Zunkel T, Steinmann J, et al. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin-2 in a myeloma model. Br J Haematol 2003;120:27.
13. Wos E, Olencki T, Tuason L, et al. Phase II trial of subcutaneously administered garnulocyte-macrophage colony-stimulating factor in patients with metastastic renal cell carcinoma. Cancer 1996;77:1149.
14. Rini BI, Stadler WM, Spielberger RT, et al. Granulocyte-macrophage- colony-stimulating factor in metastastic renal cell carcinoma: A phase II trial. Cancer 1998;82:1352.
15. Ravaud A, Delaunay M, Chevreau C, et al. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: A randomized phase II trial. Br J Cancer 2001;85:1467.
16. Spitler LE, Grossbard ML, Ernsthoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614.
17. Wang F, Bade E, Jkuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756.
18. Weber JS, Targan S, Scotland R, et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with multipeptide vaccine for resected stages IIIC and IV melanoma. [Abstract 2510] ASCO-Annual Meeting Proceedings, Part I. Atlanta, GA, June 20, 2006. 24(18S).